Flyer

Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 14
  • Journal CiteScore: 3.77
  • Journal Impact Factor: 4.09
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • International Committee of Medical Journal Editors (ICMJE)
  • Zenodo
Share This Page

Pseudo-relapse and cancer stem cells in ovarian cancer

2nd Edition of International Conference on Clinical Oncology and Molecular Diagnostics
June 11- 13, 2018 Dublin, Ireland

Martin Orlando Rosas Delgado

Sonora Cancer Research Center (CICS Sonora), Mexico

Scientific Tracks Abstracts: Arch Cancer Res

Abstract:

Background: Little information exists about the early, middle and late image effects after antigen-specific multi-peptide immunotherapy and immunomodulation in epithelial ovarian cancer. Most of the potential effects in pseudo-progression and pseudo-relapse are mainly unknown for the oncologists and radiologists, specifically in the follow up by images such as CT scan and PET scan after immune interventions are mainly unexplored clinically. We studied 30 high-grade serous carcinomas. We selected two relevant clinical image methods to demonstrate that immune infiltration attacking biologically, and clinically relevant proteins involved in cancer stem cells and prognosis produce atypical images in patients with pseudo-progression and in patients with pseudo-relapse after successful immune based treatment. We demonstrated that patients treated with this approach have atypical images. We found by PET scan bright images, multiple lymphadenopathies and necrosis nests after treatment compatible with better prognosis. Methods: 30 PET scans and CT scans were analyzed for number of enlarged lymph nodes, lesions brightness size and were analyzed by four operators. Moreover, we analyzed by Granzyme B ELISPOT the immune response against predicted Th1 and CD8 epitopes from the bad prognosis proteins during, before and after treatment. We performed univariate and multivariate analysis for clinical correlations. Results: 100% of the patients showed the same pattern in the PET and CT scan by meaning of multiple lymphadenopathies and bright areas in the previously occult microscopic cancer stem cells. We found the eight bad prognosis proteins were overexpressed in colon and upper GI tract as following RCAS1
(90%), Fascin-1 (76%), EGFR (60%), VCP (85%), Ape-1 (90%) and Sox2 (48 %). We found after treatment a media expression of CD8 cells of 40%. Discussion: Epithelial ovarian cancer is highly infiltrated by CD8 cells that induce bright color on the lesions by Pet and CT scan and we need to validate this data to have the proof of principle and avoid over treatment in epithelial ovarian cancer and importantly learn to distinguish true active malignant tumor lesions from immune infiltration that usually is misinterpreted by radiologists and some oncologist.
 

Biography :

Martin Orlando Rosas Delgado has received his Medical degree from the University of Sonora campus Hermosillo. Currently he is a 3rd year CancerVac Fellow, and he is ready to start Internal Medicine and eventually Medical Oncology. During the past three years as CancerVac fellow he initially took one year of Clinical Oncology work on CICS Sonora, one year of clinically relevant work and now he is charge of the Ovarian Refractory Clinic in order to try to rescue to all the patients out of treatment with very interesting results. He performs all the clinical histories, clinical exploration, and analysis of the PET and CT scans in order to make correlations in coordination with other members of the group of his clinical and image observation with pathological and clinical laboratory and immunology parameters. He is currently performing his own project as part of his academic formation CancerVac fellow with potential positive clinical results in refractory ovary cancer patients. He is also actively involved in the training of the first year CancerVac fellows and he deliver several courses such as Medical Biochemistry, Oncology Radiology, Medical Immunology I and II, Principles of Internal Medicine and the application and importance of the clinically relevant research.

Email:drmrosas@hotmail.com